Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C.

Bayati N, Silverman AL, Gordon SC.

Am J Gastroenterol. 1998 Dec;93(12):2452-6.

PMID:
9860408
2.

Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.

Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ.

J Gastroenterol Hepatol. 2008 Oct;23(10):1541-8. doi: 10.1111/j.1440-1746.2008.05395.x. Epub 2008 Apr 19.

PMID:
18422961
3.

Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients.

Cedrone A, Covino M, Caturelli E, Pompili M, Lorenzelli G, Villani MR, Valle D, Sperandeo M, Rapaccini GL, Gasbarrini G.

Hepatogastroenterology. 2000 Nov-Dec;47(36):1654-8.

PMID:
11149026
4.

Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alfa fetoprotein.

Izzo F, Cremona F, Delrio P, Leonardi E, Castello G, Pignata S, Daniele B, Curley SA.

Ann Surg Oncol. 1999 Mar;6(2):178-85.

PMID:
10082044
5.

Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.

Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R.

Am J Gastroenterol. 2000 Apr;95(4):1036-40.

PMID:
10763956
6.

Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C.

Bruce MG, Bruden D, McMahon BJ, Christensen C, Homan C, Sullivan D, Deubner H, Williams J, Livingston SE, Gretch D.

J Viral Hepat. 2008 Mar;15(3):179-87. doi: 10.1111/j.1365-2893.2007.00928.x.

PMID:
18233991
7.

The predictive ability of serum alpha-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance.

Huo TI, Hsia CY, Chu CJ, Huang YH, Lui WY, Wu JC, Lee PC, Chi CW, Lee SD.

J Surg Oncol. 2007 Jun 15;95(8):645-51.

PMID:
17530668
8.

Clinical significance of elevated alpha-fetoprotein (AFP) in chronic hepatitis C without hepatocellular carcinoma.

Chen CH, Lin ST, Kuo CL, Nien CK.

Hepatogastroenterology. 2008 Jul-Aug;55(85):1423-7.

PMID:
18795704
9.

Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis.

Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB.

Hepatology. 2002 Aug;36(2):410-7.

PMID:
12143050
10.

Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.

Gadelhak NA, Gadelhak SA, El-Morsi DA, Abdelaziz MM, Abbas AT, El-Emshaty HM.

Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1417-24.

PMID:
19950803
11.

Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.

Rodríguez-Díaz JL, Rosas-Camargo V, Vega-Vega O, Morales-Espinosa D, Mendez-Reguera A, Martínez-Tlahuel JL, Gamboa-Domínguez A, Arrieta O.

Clin Oncol (R Coll Radiol). 2007 Apr;19(3):197-203. Epub 2007 Jan 18.

PMID:
17359907
12.

Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.

Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH.

Clin Cancer Res. 2008 Jan 15;14(2):470-7. doi: 10.1158/1078-0432.CCR-07-0586.

14.

Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.

Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, Carroccio A, Sesti R, Tripi S, Montalto G.

Anticancer Res. 2003 Mar-Apr;23(2C):1747-53.

PMID:
12820452
15.

Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C.

Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, Li CP, Wu JC, Chang FY, Lee SD.

J Clin Gastroenterol. 2001 Mar;32(3):240-4.

PMID:
11246354
16.

Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis.

Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME.

Am J Gastroenterol. 2007 Oct;102(10):2196-205. Epub 2007 Jul 7.

PMID:
17617202
17.

Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma.

Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T.

Am J Gastroenterol. 2004 May;99(5):860-5.

PMID:
15128351
18.

Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.

Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME, Sherman M.

Clin Gastroenterol Hepatol. 2009 Jan;7(1):104-13. doi: 10.1016/j.cgh.2008.08.041. Epub 2008 Sep 17.

PMID:
18849011
19.

Diagnosis of hepatocellular carcinoma by concanavalin A affinity electrophoresis of serum alpha-fetoprotein.

Saitoh S, Ikeda K, Koida I, Suzuki Y, Kobayashi M, Tsubota A, Arase Y, Chayama K, Murashima N, Kumada H.

Cancer. 1995 Oct 1;76(7):1139-44.

20.

Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.

Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR; HALT-C Trial Group..

J Hepatol. 2005 Sep;43(3):434-41.

PMID:
16136646

Supplemental Content

Support Center